We are live on ! Find out more
SCLN

Sciclone Pharmaceuticals Inc
SCLN

Delisted

SCLN was delisted on the 13th of October, 2017.

131 hedge funds and large institutions have $652M invested in Sciclone Pharmaceuticals Inc in 2014 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 47 increasing their positions, 42 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

213% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 8

206% more capital invested

Capital invested by funds: $213M → $652M (+$439M)

13% more funds holding

Funds holding: 116131 (+15)

12% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 42

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

35% less call options, than puts

Call options by funds: $608K | Put options by funds: $939K

Holders
131
Holders Change
+15
Holders Change %
+12.93%
% of All Funds
3.49%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.03%
New
25
Increased
47
Reduced
42
Closed
8
Calls
$608K
Puts
$939K
Net Calls
-$331K
Net Calls Change
-$168K
Name Holding Trade Value Shares
Change
Change in
Stake
ProShare Advisors
76
ProShare Advisors
Maryland
$391K -$16.9K -2,082 -4%
MLICM
77
Metropolitan Life Insurance Company (MetLife)
New York
$385K
BPGAM
78
BTG Pactual Global Asset Management
Bermuda
$384K +$355K +43,829 New
AQR Capital Management
79
AQR Capital Management
Connecticut
$382K +$240K +29,700 +214%
AL
80
Airain Ltd
Guernsey
$377K +$35.5K +4,385 +11%
Jacobs Levy Equity Management
81
Jacobs Levy Equity Management
New Jersey
$374K +$93.1K +11,500 +37%
Tudor Investment Corp
82
Tudor Investment Corp
Connecticut
$361K -$7.12K -879 -2%
HIM
83
Hillsdale Investment Management
Ontario, Canada
$360K +$333K +41,100 New
GMIM
84
General Motors Investment Management
New York
$332K
Arrowstreet Capital
85
Arrowstreet Capital
Massachusetts
$325K +$300K +37,063 New
VOYA Investment Management
86
VOYA Investment Management
Georgia
$323K
Public Employees Retirement Association of Colorado
87
Public Employees Retirement Association of Colorado
Colorado
$312K
Bank of America
88
Bank of America
North Carolina
$303K -$65.3K -8,063 -19%
Deutsche Bank
89
Deutsche Bank
Germany
$292K +$84.4K +10,423 +45%
AIG
90
American International Group
New York
$284K -$10.4K -1,282 -4%
PA
91
Perceptive Advisors
New York
$262K +$113K +13,907 +87%
UBS AM
92
UBS AM
Illinois
$256K +$24.3K +3,000 +11%
DIA
93
Denver Investment Advisors
Colorado
$249K -$104K -12,910 -31%
DekaBank Deutsche Girozentrale
94
DekaBank Deutsche Girozentrale
Germany
$239K -$20.2K -2,500 -8%
BG
95
BlackRock Group
United Kingdom
$232K
QI
96
Quotient Investors
New York
$230K
Allianz Asset Management
97
Allianz Asset Management
Germany
$227K -$4.74K -585 -2%
First Trust Advisors
98
First Trust Advisors
Illinois
$210K -$19.1K -2,357 -9%
Citigroup
99
Citigroup
New York
$191K +$143K +17,671 +419%
CSS
100
Cubist Systematic Strategies
Connecticut
$185K -$118K -14,575 -41%

SCLN Hedge Fund Activity: Q4 2014 in Review

131 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Sciclone Pharmaceuticals Inc (SCLN) for Q4 2014, worth a combined $652M — up 206% from $213M a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new SCLN positions and 8 closed out — a net gain of 17 holders — while 47 added to existing stakes and 42 trimmed.

The largest buyer was McKinley Capital Management, opening a new position worth an estimated $6.86M. The largest seller was LSV Asset Management, cutting an estimated $4.19M.

  • 131 institutional investors held Sciclone Pharmaceuticals Inc (SCLN) as of Q4 2014, up from 116 in Q3 2014.
  • Funds reported $652M of Sciclone Pharmaceuticals Inc stock for Q4 2014, up 206% quarter-over-quarter.
  • 25 funds opened new Sciclone Pharmaceuticals Inc positions in Q4 2014 and 8 closed out, a net change of +17 holders.
  • The largest Sciclone Pharmaceuticals Inc buyer in Q4 2014 was McKinley Capital Management, an estimated $6.86M added.
  • The largest Sciclone Pharmaceuticals Inc seller in Q4 2014 was LSV Asset Management, an estimated $4.19M sold.

Based on aggregated 13F filings for Q4 2014.